(doxorubicin, epirubicin, idarubicin, daunorubicin, mitoxantrone)

Cardio-oncological evaluation* and troponin**

before cancer treatment begins


after each cycle (end of infusion)***

Troponin +

Cardio-oncological evaluation*

before the next cycle

Troponin -

Cardio-oncological evaluation*

at the end of cancer treatment and then at 6 months, 1 year, 2 years, and periodically thereafter

* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.


**Assays should be carried out by the same laboratory (same type of troponin, same method of measurement).

Troponin + if >99e percentile of the URL


***Cardiological evaluation should be performed before each cycle if the cumulative dose:

-Doxorubicn > 250 mg/m2

-Epirubicin > 600 mg/m2

-Idarubicin > 48 mg/m2

-Daunorubicin > 288 mg/m2

-Mitoxantrone > 60 mg/m2

Logo final.png

Centre Méditerranéen Hospitalo-Universitaire de Cardio-Oncologie

​Hôpital Nord, chemin des Bourrely, 13015 Marseille, France

Aix-Marseille Université

Nous contacter

  • Facebook Social Icône


© 2020 by Franck Thuny